FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
21/03/2023
Voltar para busca
Dado oficial do USPTO
B
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
27
Atualização mais recente
21/03/2023
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
24/05/2021
Data de registro
01/11/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/11/2022
Última transação
01/11/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
CN
Examinador
BLOHM, LINDA
Unidade examinadora
M10
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the left-slanting capital letter "B" in blue and the parallelogram on the upper left corner of the "B" in green. The white background is not claimed as a feature of the mark.
Titulares e representantes
Titulares
Chengdu Brilliant Pharmaceutical Co., Ltd.
Representantes
Paulo A. de Almeida Patel & Almeida, P.C.
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Cultures of microorganisms for medical or veterinary use; medical dressings; pharmaceutical preparations for human use for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; pharmaceutical preparations for human use for the prevention and treatment of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disordersdiabetes; pharmaceutical preparations for human use for the treatment of infectious diseasesblood disorderspaininflammationsepsisalopeciaobesity and cognitive disorders; pharmaceutical preparations for human useanti-infectives; antifungal pharmaceutical preparations for human use; Chinese traditional medicinal herbs for human use; pharmaceutical preparations for human use for antitussive-cold; pharmaceutical preparations for human use for the prevention and treatment of cancer; pharmaceutical preparations for human use for the treatment of psychiatric diseases and disorders; pharmaceutical preparations for human use for the treatment of heart rhythm disorders; medicated throat sprays for human use; diuretic pharmaceutical preparations for human use; pharmaceutical preparations for human use for the treatment of musculo-skeletal disorders; pharmaceutical preparations for human use for the treatment of hyperlipidemia; antitussives for human use; otorhinolaryngological pharmaceutical preparations for human use; anaesthetics for human use; pharmaceutical preparations for humanantidepressants; pharmaceutical preparations for human use for the treatment of eye diseases and conditions; headache treatment pharmaceutical preparations for human use; nasal spray preparations for human use; medicines for human use for the treatment of gastrointestinal diseases; medicinal preparations for the mouth and as sprays for human use; thyroid and para-thyroid hormone pharmaceutical preparations for human use; sulfonamide pharmaceutical preparations for human use; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension for human use; pharmaceutical preparations acting on the central nervous system for human use; pharmaceutical preparations for human use for the treatment of erectile dysfunction; pharmaceutical solutions used in dialysis for human use; pharmaceutical preparations for human use for the treatment of bone diseases; antipyretic analgesics for human use; antiallergic medicines for human use; anti-diabetic pharmaceutical preparations for human use; hypnotic sedatives for human use; cardiovascular pharmaceutical preparations for medical purposes for human use; hemostatics for medical purposes for human use; antihemorrhoidal pharmaceutical preparations for human use; anti-epileptic pharmaceutical preparations for human use; cerebral hemorrhage prophylactic pharmaceutical preparations for human use; pharmaceutical preparations for human use for the treatment of immune system related diseases and disorders; pharmaceutical preparations for human use for treating hypertension; athlete's foot pharmaceutical preparations for human use; pharmaceutical preparations for human use for treating asthma; pharmaceutical preparations for human use for the treatment of hormonal disorders; medicated mouth treatment pharmaceutical preparations for human use; motion sickness medicines for human use; diarrhea medication for human use; pesticides; medicines for veterinary purposespain relief medication; veterinary vaccines; anti-infectives products for veterinary use; bacteriological medicinal preparations for veterinary purposes; medicines for veterinary purposesfor treatment of intestinal bacteria; medicines for veterinary purposes for the treatment of animals' skin diseases; medicines for veterinary purposes for the treatment of wounds; albumin dietary supplements for medical purposes; depuratives for the body; oxygen for medical purposes; nitrous oxide for medical use; radioactive substances for medical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
27 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
28/02/2023
FIMP
FINAL DISPOSITION PROCESSED
27/02/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/02/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/11/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
01/11/2022
DOCK
ASSIGNED TO EXAMINER
17/10/2022
GPNX
NOTIFICATION PROCESSED BY IB
17/08/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16/08/2022
PUBO
PUBLISHED FOR OPPOSITION
16/08/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/07/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/07/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
27/07/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/07/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/07/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/07/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/07/2022
RFNT
REFUSAL PROCESSED BY IB
04/04/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
14/03/2022
RFRR
REFUSAL PROCESSED BY MPU
14/03/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/02/2022
CNRT
NON-FINAL ACTION WRITTEN
11/02/2022
DOCK
ASSIGNED TO EXAMINER
04/02/2022
MAFR
APPLICATION FILING RECEIPT MAILED
12/11/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/11/2021
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
05/11/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
29/10/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace B ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.